IMMUNOLOGY2026™ Conference Recordings For Attendees-Inflammasome pathway inhibition in autoinflammatory diseases

Video Transcription

Video Summary

The speaker presented research on inflammasome biology and a Novartis investigational bispecific antibody, MAS825 (arumakimig), which targets both IL-1β and IL-18. He explained that inflammasome overactivation drives inflammatory disease, especially severe autoinflammatory conditions like Still’s disease, where many patients remain ill despite IL-1 or IL-6 blockade. MAS825 showed synergistic activity in preclinical assays and favorable pharmacodynamic effects in healthy volunteers. In a COVID-19 pneumonia study, it produced biomarker improvements, including reduced IL-6, CRP, and interferon-γ. Ongoing trials are now testing MAS825 in monogenic IL-18-driven diseases and difficult-to-treat Still’s disease. He also highlighted compassionate-use case reports suggesting benefit in refractory patients. Finally, he discussed human caspase-1 loss-of-function genetics, where individuals appeared to live normally with minimal health consequences, informing thoughts about the safety of chronic inflammasome inhibition and its potential cardiovascular applications.

Meta Tag

Date April 17, 2026 9:45 AM - 11:15 AM

Room 151

Session Translating Human Immunology Through Cytokine Research, Sponsored by the Intl. Cytokine and Interferon Soc. (ICIS)

Speaker Michael Badman

Track Cytokines and Chemokines and their Receptors (CCR)

Year 2026

Keywords

inflammasome

MAS825

IL-1β

IL-18

Still’s disease

April 17, 2026 9:45 AM - 11:15 AM

151

Translating Human Immunology Through Cytokine Research, Sponsored by the Intl. Cytokine and Interferon Soc. (ICIS)

Michael Badman

Cytokines and Chemokines and their Receptors (CCR)

2026